Navidea Biopharma (NAVB) Reports Q4 Loss of $0.11

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.11). Revenue for the quarter came in at $1 million, versus $0 reported last year.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• NVE Corporation names new CEO and expands board to seven members